Posts tagged exclusive license
IntelGenx gets oral film exclusivity for tadalafil ED dosing patent

IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that Eli Lilly granted IntelGenx’s VersaFilm an exclusive license for a tadalafil film product under its 6,943,166 erectile dysfunction (ED) dosing patent. Any exclusivity associated with the tadalafil compound patent expiring is not affected by this agreement.  

Read More
Knight takes stake in 3D Signatures

Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.

3D is a personalized medicine company, with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease.

Read More
Incyte to acquire ARIAD’s EU operations, in-license Iclusig

Incyte (NASDAQ:INCY) has agreed to acquire ARIAD Pharmaceuticals’ (NASDAQ:ARIA) European operations. At the expected June 1 closing of the transaction, Incyte will obtain an exclusive license to develop and commercialize Iclusig in Europe and other select countries.

The agreement to divest its European operations and out-license Iclusig in Europe will enable ARIAD to focus its promotion of Iclusig on the highly valuable U.S. market, while strengthening its financial position and maintaining important optionality through a potential buy-back provision for the Iclusig license rights in the event of a change-in-control of ARIAD.

Read More